Expert Interviews

How SBRT Has Evolved Over the Decades to Manage Kidney Cancer
December 03, 2022

An expert from the University of Texas Southwestern Medical Center in Dallas gives an overview of the multimodal use of stereotactic radiation for the treatment of patients with metastatic kidney cancer.

Stereotactic Radiation Offers ‘Another Modality’ for the Management of Metastatic Kidney Cancer, Says Expert
December 02, 2022

An expert from the University of Texas Southwestern Medical Center in Dallas emphasized that stereotactic radiation provides oncologists with an alternative modality for treating patients with kidney cancer for whom standard ablative surgery.

Prospective Data Establishing the Clinical Utility of Testing All Biomarkers in Advanced Bladder Cancer is Still Needed, Says Expert
December 01, 2022

With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.

Defining Frail Patients in Multiple Myeloma
December 01, 2022

Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.

Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM
December 01, 2022

Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.

Treating High-Risk Transplant-Ineligible Newly Diagnosed Multiple Myeloma
December 01, 2022

Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.

Transplant-Ineligible NDMM: Optimizing Selection and Duration of Therapy
December 01, 2022

Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.

Sacituzumab Govitecan in mTNBC: Results From the ASCENT Study
November 30, 2022

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Metastatic Triple-Negative Breast Cancer: An Evolving Treatment Landscape
November 30, 2022

Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.

Explaining Molecular Testing to Patients with Metastatic Colorectal Cancer
November 30, 2022

Elle Charnisky describes her experience with molecular testing, and Nurse Practitioner Deanna Griffie details how she explains testing to patients with metastatic colorectal cancer.